title: A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
abstract: OBJECTIVE
  High-dose intermittent cytarabine is an effective postremission treatment for patients with acute myeloid leukemia (AML). This regimen is a safe approach in patients < 60 years but produced severe neurotoxicity in the elderly.
  
  
  METHODS
  We have established a dose-reduced age-adapted consolidation using intermediate dose (IDAC; 2 x 1 g/m(2) i.v., days 1, 3, and 5) for AML patients >/= 60 years. Forty-seven de novo AML patients in complete remission (CR; median age, 70 years) were scheduled to receive four consolidation cycles of IDAC.
  
  
  RESULTS
  In 25 of 47 patients (53%), all four cycles were administered: 9 (19%) received three cycles; 7 (15%) received two cycles; and 6 patients (12%) one cycle. Treatment was well tolerated without neurotoxicity. The median number of days with severe neutropenia (absolute neutrophil count < 500/microl) was 9. Neutropenic fever occurred in 22 of 47 patients (49%) during the first cycle, in 24 of 41 (60%) during the second, in 15 of 34 (44%) during the third, and in 18 of 25 (72%) during the fourth cycle. Only 1 patient died during consolidation (cardiac failure). The median overall survival, disease-free survival, and continuous CR were 10.6, 15.5, and 15.9 months, respectively. The probability of overall survival, disease-free survival, and continuous CR at 5 years were 18, 22, and 30%, respectively.
  
  
  CONCLUSIONS
  IDAC is a safe and effective postremission therapy for elderly patients with AML.
authors.affiliation: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Institute of Medical Biology, and Institute of Medical and Laboratory Medicine, Medical University of Vienna, Vienna, Austria. wolfgang.r.sperr@univie.ac.at
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Sperr
authors.forename: Maria
authors.initials: M
authors.lastname: Piribauer
authors.forename: Friedrich
authors.initials: F
authors.lastname: Wimazal
authors.forename: Christa
authors.initials: C
authors.lastname: Fonatsch
authors.forename: Renate
authors.initials: R
authors.lastname: Thalhammer-Scherrer
authors.forename: Ilse
authors.initials: I
authors.lastname: Schwarzinger
authors.forename: Klaus
authors.initials: K
authors.lastname: Geissler
authors.forename: Paul
authors.initials: P
authors.lastname: Knöbl
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jäger
authors.forename: Klaus
authors.initials: K
authors.lastname: Lechner
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin